# Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

> **NCT01741545** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 71 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **BIOLOGICAL:** Pegylated-Interferon-lambda
- **DRUG:** Ribavirin
- **DRUG:** Daclatasvir

## Key facts

- **NCT ID:** NCT01741545
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-31
- **Primary completion:** 2015-01-31
- **Final completion:** 2015-01-31
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01741545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01741545, "Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01741545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*